Cullinan Therapeutics, Inc. (CGEM)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Cullinan Therapeutics’ loss per share was slightly wider than consensus, with preliminary results for the second fiscal quarter of 2026 reported August 6, 2026 showing EPS of -$0.81 trailed the -$0.80 estimate by -$0.01, while the company continued to operate as a clinical-stage oncology developer across programs such as CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. Net income improved ~23% year over year to about -$53.7 million (up from -$70.1 million a year ago), alongside a ~24% year-over-year improvement in EPS from -$1.07. Operating income for the quarter was about -$57.3 million, and the company generated negative operating cash flow of roughly -$38.2 million, reflecting ongoing spend to advance its pipeline rather than support a marketed product base. For the next period, consensus calls for EPS of -$0.85 on revenue of $2.0 million.
Next report — what to expect
Cullinan Therapeutics, Inc. (CGEM) reports next on November 5, 2026. Wall Street’s next-period consensus calls for EPS of -$0.844 on revenue of $2.0 million. Heading into the print, the company has beaten EPS in 6 of 8 most recent quarters, making the EPS line a key item to watch versus expectations.
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on developing cancer treatments that draw on the immune system. Trading as CGEM, it operates as a clinical-stage drug developer in healthcare, advancing a pipeline of oncology candidates rather than a marketed product portfolio.
Today's Snapshot
CGEM closed 3.7% lower at 14.37, in line with a weaker sector. Trading was lighter than usual, with volume about two-thirds of its usual level. BTIG Research, an analyst firm, kept its recommendation to buy Cullinan Therapeutics shares.
Trading Volume
Below 10d avg (708.7K)
485.2K
vs S&P 500 Today
Strong Underperformance
-3.17%
Updated: October 23, 2026 at 20:24 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$14.60 - $16.97Sell
- RSI (14)39.68Neutral
- Stochastic %K (14, 3, 3)39.69Neutral
- MACD Level (12, 26)-1.08Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.